Bicycle Therapeutics plc today announced that on July 1, 2025, the Compensation Committee of the company’s Board of Directors granted to eight new employees inducement awards consisting of non-qualified share…
The 40th barometer from Sermo, a fast, frictionless HCP engagement platform providing the healthcare industry with real-time business insights and authentic physician touch points, of 1,000+ global healthcare providers (HCPs) found…
Clinical Results of iPSC-CAR-NK Cell Therapy Published in Cell, Marking a Global Breakthrough in Autoimmune Disease Treatment Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an…
Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets. The…
Today released its fifth annual Healthcare Consumer Report, unveiling key insights into consumer sentiment about their health insurance plans. This year’s findings highlight the growing importance of affordability, transparency, member…
FDA Approves KEYTRUDA® for PD-L1+ Head & Neck Cancer in Neoadjuvant and Adjuvant Settings Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the…
Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a…
MDP Completes Acquisition of Significant Ownership Position in NextGen Healthcare and Partners with Thoma Bravo and Company Management to Accelerate NextGen Healthcare’s Growth NextGen Healthcare President and COO Srinivas (Sri)…
Growve, a leader in the health and wellness industry, announced today that it has secured a majority equity investment led by Palm Beach Capital (PBC), with participation from G-Bar Ventures and NMP Capital. As…
Nu Skin Enterprises (NUS: NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company’s board of directors. He was elected by shareholders…
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6…
Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) and granted Priority Review designation for the investigational compound sevabertinib (BAY…